Literature DB >> 16019628

Treatment of chromoblastomycosis with terbinafine: a report of four cases.

Z Xibao1, L Changxing, L Quan, H Yuqing.   

Abstract

This report is about four cases of chromoblastomycosis confirmed by direct examination, histopathology and cultures. The duration of disease infection varied from 5 to 12 years. By culture, Cladosporium carrionii was isolated in two cases and Fonsecaea pedrosoi in the other two cases. Terbinafine 0.25 g twice daily for 1 month and 0.25 g once daily for maintenance therapy were given to three patients. Terbinafine 0.25 g once daily was given to one patient. After 4-8 months of therapy, all cases were cured without relapse when followed up for 6 months. The total dosage of terbinafine was 37.5-60 g. No relevant side effects showed during treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16019628     DOI: 10.1080/09546630510033203

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  5 in total

1.  Chromoblastomycosis Caused by Phialophora richardsiae.

Authors:  Young-Min Son; Hong-Kyu Kang; So-Young Na; Hye-Young Lee; Jin-Ok Baek; Jong-Rok Lee; Joo-Young Roh; Yiel-Hea Seo
Journal:  Ann Dermatol       Date:  2010-08-05       Impact factor: 1.444

Review 2.  Challenges in the therapy of chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Daniel Wagner de C L Santos
Journal:  Mycopathologia       Date:  2013-05-02       Impact factor: 2.574

Review 3.  Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics.

Authors:  Sha Lu; Changming Lu; Junmin Zhang; Yongxuan Hu; Xiqing Li; Liyan Xi
Journal:  Mycopathologia       Date:  2012-10-20       Impact factor: 2.574

4.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

Review 5.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.